Key result
Enoxaparin thromboprophylaxis yields a ~3% 90-day VTE rate in hospitalized patients with obesity.
Why the study?
Patients with obesity hospitalized for acute medical illness face increased VTE risk, but evidence on predictors of VTE and major bleeding to optimize risk stratification and thromboprophylaxis remains limited, particularly in extreme obesity.
Cohort (n=58,186)
Yes
In obese patients hospitalized for acute medical illnesses, 90-day VTE event rates (3.2%) are nonnegligible and exceed major bleeding rates (1.8%), despite over half receiving high-dose weight-adjusted enoxaparin, highlighting a vulnerable population in need of optimized prophylactic strategies.
Answers are grounded in this paper and cite their sources.
Supports evaluation of optimized thromboprophylaxis in obese medical inpatients; leaves open comparative efficacy of dosing regimens in randomized trials.
Background: Patients with obesity hospitalized for acute medical illness are at increased venous thromboembolism (VTE) risk, but evidence on predictors of VTE and major bleeding (MB) to optimize individual risk stratification and thromboprophylaxis remains limited, in particular for patients with extreme obesity. Objectives: This study assessed pharmacologic regimen, event rates, and predictors for VTE and MB among hospitalized medical patients with obesity receiving thromboprophylaxis using enoxaparin. Methods: hospitalized for acute medical illness who received thromboprophylaxis with enoxaparin were selected from the Optum database. Event rates over a 90-day follow-up after enoxaparin initiation were estimated via the Kaplan-Meier method. Factors associated with outcome events were identified via Cox proportional hazard models. Results: ; 56.9% received high-dose enoxaparin (>40 mg), and 42.8% received the standard dose (≤40 mg). The median duration of enoxaparin prophylaxis (3 days) was shorter than the length of the hospitalization (4 days). The 90-days cumulative incidence was 3.2% (95% CI, 3.1-3.4) for VTE and 1.8% (95% CI, 1.7-1.9) for MB. The highest VTE rates were observed in patients with cancer-related hospitalizations (7.8%). A history of VTE and MB were the strongest predictors of VTE (HR, 4.1; 95% CI, 3.6-4.7) and MB (HR, 2.8; 95% CI, 2.0-3.7), respectively. Conclusion: Acutely ill patients with obesity received enoxaparin for shorter duration than their hospitalization, with over half receiving a high-dose adjustment by weight. The VTE rates were nonnegligible in this population and exceed MB rates across illness subgroups, suggesting a need for individualized risk stratification to optimize thromboprophylaxis.
No takes yet. Share an insight, caveat, or question.
Ageno et al. (2026) conducted a cohort in Acute medical illness with obesity (n=58,186). Enoxaparin was evaluated on 90-day cumulative incidence of venous thromboembolism (VTE) (95% CI 3.1-3.4). Among hospitalized acutely ill patients with obesity receiving enoxaparin thromboprophylaxis, the 90-day cumulative incidence of venous thromboembolism was 3.2%.
Synapse has enriched 10 related papers. Consider them for comparative context: